No early win for Sanofi, Regeneron cholesterol drug in study

Nov 17 (Reuters) - Sanofi and Regeneron Pharmaceuticals said on Thursday they would continue a large clinical outcomes study with their injectable cholesterol-lowering drug Praluent.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.